Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02035020
Recruitment Status : Completed
First Posted : January 14, 2014
Last Update Posted : April 21, 2017
Information provided by (Responsible Party):
Carlo Casali, Azienda Policlinico Umberto I

Brief Summary:
The primary objective of this study is to investigate whether the treatment with IFN gamma can induce significant accumulation of frataxin in FRDA patients, a possibility suggested by pre-clinical evidence in an animal model of the disease.

Condition or disease Intervention/treatment Phase
Friedreich Ataxia Drug: gamma interferon Phase 2

Detailed Description:
This is a Phase 2 clinical trial. A total of 10 FRDA patients will be recruited All subjects will be treated with a dose of 100-150-200-micrograms of IFN gamma 1b (Imukin®) subcutaneously, with an interval of 14 days, for a total of 3 injections.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IIa Clinical Trial to Test the Safety and Efficacy of Interferon Gamma Treatment in Elevating Frataxin Levels in Friedreich's Ataxia (FRDA) Patients
Study Start Date : May 2013
Actual Primary Completion Date : July 30, 2014
Actual Study Completion Date : July 30, 2014

Arm Intervention/treatment
Experimental: Gamma interferon
IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
Drug: gamma interferon
IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
Other Name: Imukin

Primary Outcome Measures :
  1. Change in cellular frataxin [ Time Frame: 24 hours and 7 days from each study drug administration ]
    The primary endpoint is to test the increase of cellular frataxin after treatment with IFN gamma. Quantitation of cellular frataxin will be performed after 24 hours and 7 days from each study drug administration

Secondary Outcome Measures :
  1. Safety Blood sample [ Time Frame: day 0-14-28-35 ]
    Secondary endpoint is the safety and tolerability of IFN gamma in FRDA patients. The on treatment adverse events and withdrawals due to adverse effects will be reported. Any subject who receives at least 1 dose of investigational product will be included in the evaluation for safety

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. FRDA patients should have their diagnosis genetically confirmed.
  2. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
  3. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  4. Male and/or female subjects between the ages of > 18 and < 45 years


Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. Significant concurrent medical conditions at the time of screening or baseline visit, including, but not limited to, the following:

    • Any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, GI, endocrine, pulmonary, immunologic, or local active infection/infectious illness) that, in the investigator's judgment, will substantially increase the risk to the subject if he or she participates in the study.
    • Class III or IV congestive heart failure as defined by the New York Heart Association.
    • Acute coronary syndrome (eg, myocardial infarction, unstable angina pectoris) and any history of significant cerebrovascular disease within 24 weeks before screening.
  3. Presence of a transplanted organ.
  4. Previous assumption of IFN gamma 1b.
  5. Abnormality in any of the below hematology or chemistry profile values at screening:

    • Positive hepatitis B surface antigen (HBsAg), Total hepatitis B core antibody (HBcAb; also called anti HBc), and/or hepatitis C antibody (HCVAb) with confirmation by hepatitis C virus ribonucleic acid (HCV RNA).
    • ALT/AST levels > or = 1.5X ULN.
    • Total bilirubin level > or = 1.5 times the ULN.
    • Hemoglobin level < or = 80 gL (8.0 g/dL).
    • Platelet count < or = 100 x 109/L (100,000 cells/mm³) or > or = 1000 x 109/L (1,000,000 cells/mm³).
    • White blood cell count < or = 3.5 x 109/L (3500 cells/mm³).
    • Absolute neutrophil count (ANC) <2000 cells/mm³.
    • Serum creatinine level > or = 177 μmol/ L (2 mg/dL).
    • Glycosylated hemoglobin (HbA1c >10%).
  6. Current or history of serious psychiatric disorder or alcohol or drug abuse.
  7. Participation in other studies within 30 days before screening and/or during study participation.
  8. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or ability to comply with study procedures, investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02035020

Layout table for location information
Policlinico Umberto I°
Rome, Italy/Rome, Italy, 00161
Sponsors and Collaborators
Azienda Policlinico Umberto I
Layout table for investigator information
Principal Investigator: Carlo Casali, MD Policlinico Umberto I°
Layout table for additonal information
Responsible Party: Carlo Casali, Professor, Azienda Policlinico Umberto I Identifier: NCT02035020    
Other Study ID Numbers: GIFT/1
First Posted: January 14, 2014    Key Record Dates
Last Update Posted: April 21, 2017
Last Verified: April 2017
Keywords provided by Carlo Casali, Azienda Policlinico Umberto I:
frataxin, gamma interferon, Friedreich ataxia
Additional relevant MeSH terms:
Layout table for MeSH terms
Cerebellar Ataxia
Friedreich Ataxia
Neurologic Manifestations
Nervous System Diseases
Cerebellar Diseases
Brain Diseases
Central Nervous System Diseases
Spinocerebellar Degenerations
Spinal Cord Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Mitochondrial Diseases
Metabolic Diseases
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents